Oric Pharmaceuticals (ORIC) News Today

Oric Pharmaceuticals logo
$7.98 +0.46 (+6.08%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Why Is Oric Pharmaceuticals Up Today?

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) received bullish analyst support, while its third-quarter loss and higher clinical-trial spending were headwinds. The company also advanced its Phase 3 program with a new trial launch.

  • Positive Sentiment: Citigroup raised its price target to $17 from $16 and maintained a Buy rating, implying substantial upside from the share price cited in the report. Citigroup rating
  • Positive Sentiment: BTIG Research reaffirmed its Buy rating and $26 price target, signaling confidence in ORIC’s potential. BTIG Research rating
  • Positive Sentiment: ORIC initiated the global Phase 3 Himalayas-1 trial of rinzimetostat in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone. The study is supported by a clinical-trial collaboration and supply agreement with Bayer, marking progress toward a potential pivotal data readout. Company earnings and program update
  • Negative Sentiment: ORIC reported a third-quarter loss of $0.44 per share, wider than analysts’ expected $0.39 loss. A report attributed the widening loss to increased Phase 3 spending, highlighting the costs and execution risks of advancing its pipeline. Q3 earnings analysis
Posted 1h agoAI Generated. May Contain Errors.

Oric Pharmaceuticals Latest News

Oric Pharmaceuticals (NASDAQ:ORIC) Issues Earnings Results
BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
ORIC Pharmaceuticals Inc 4TZ

Oric Pharmaceuticals Media Mentions By Week

Oric Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ORIC
News Sentiment
▼
0.36

0.57
▲
Average
Healthcare
News Sentiment

Oric Pharmaceuticals News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ORIC Articles
This Week
▼
9

4
▲
ORIC Articles
Average Week

Oric Pharmaceuticals Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
1
Page Views
1,082
-16%
Get Oric Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Oric Pharmaceuticals dated 11/17/2026.
From Our Partners